Sotorasib versus docetaxel: evidence supporting CodeBreaK 200.

Paz-Ares, Luis; Mehta, Bhakti; Wang, Yang; Waterhouse, David; de Langen, Adrianus Johannes

Paz-Ares, Luis; Mehta, Bhakti; Wang, Yang; Waterhouse, David; de Langen, Adrianus Johannes.

Affiliation

Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Complutense University and Ciberonc, Madrid, Spain. Electronic address: lpazaresr@seom.org.
Mehta B; Amgen, Thousand Oaks, CA, USA.
Wang Y; Amgen, Thousand Oaks, CA, USA.
Waterhouse D; Oncology Hematology Care, Cincinnati, OH, USA.
de Langen AJ; Netherlands Cancer Institute, Amsterdam, Netherlands.

Lancet Oncol ; 25(8): e334, 2024 Aug.

Article in En | MEDLINE | ID: mdl-39089308

Subject(s)

Docetaxel; Humans; Docetaxel/therapeutic use; Randomized Controlled Trials as Topic; Male; Antineoplastic Agents/therapeutic use; Antineoplastic Agents/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Docetaxel Limits: Humans / Male Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google